- Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors
-
In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.
- Jin, Fangfang,Hu, Qiyue,Fei, Hongbo,Lv, Hejun,Wang, Shenglan,Gui, Bin,Zhang, Junzhen,Tu, Wangyang,Zhang, Yun,Zhang, Lei,Wan, Hong,Zhang, Limin,Hu, Bin,Yang, Fanglong,Bai, Chang,He, Feng,Zhang, Lianshan,Tao, Weikang
-
supporting information
p. 195 - 201
(2021/02/06)
-
- ortho-Phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate
-
Provided herein are novel ortho-Phthalaldehyde (OPA) containing linkers (OPA-L) and the use of OPA-L for the preparation of Antibody-drug conjugate (ADC) via the formation of Phthalimidine through the reaction of primary amine on antibody (e.g., residue o
- -
-
Page/Page column 29; 32-35
(2020/06/10)
-
- MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS
-
A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification
- -
-
Paragraph 0029;0030
(2016/04/26)
-
- Decomposition of 1-(ω-aminoalkanoyl)guanidines under alkaline conditions
-
The decomposition of some NG-(ω-aminoalkanoyl)argininamides, which are key intermediates for the preparation of radiolabeled and fluorescent neuropeptide Y receptor ligands, prompted us to synthesize a small series of simple 1-(ω-aminoalkanoyl)guanidines, and to investigate these model compounds for stability in alkaline buffers. The degradation of acylguanidines was monitored by time resolved UV spectroscopy. The most labile compound, 1-(5-aminopentanoyl)guanidine, decomposed with a half life of 19 s to yield piperidin-2-one (pH 10.4 at 25 °C). In contrast the half life of 1-(6-aminohexanoyl)guanidine is 7.7 h, which is comparable to the hydrolysis of acetylguanidine (t1/2 = 9.6 h) in alkaline solution.
- Brennauer, Albert,Keller, Max,Freund, Matthias,Bernhardt, Günther,Buschauer, Armin
-
p. 6996 - 6999
(2008/03/12)
-
- Halogenated sulfonamide derivatives
-
This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutic
- -
-
Page/Page column 10
(2010/11/28)
-
- Pyrimidine compounds
-
This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.
- -
-
Page/Page column 122-124
(2008/06/13)
-
- Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1
-
A series of 4-(dimethylamino)quinazoline based antagonists of the melanin-concentrating hormone receptor 1 (MCH-R1) is described. This series was derived from a lead compound, AR129330, identified by HTS of a GPCR-directed library using a functional assay with a constitutively activated (CART) form of the receptor. The preliminary optimization resulted in the identification of compounds 20, 21, and 23.
- Kanuma, Kosuke,Omodera, Katsunori,Nishiguchi, Mariko,Funakoshi, Takeo,Chaki, Shigeyuki,Semple, Graeme,Tran, Thuy-Anh,Kramer, Bryan,Hsu, Debbie,Casper, Martin,Thomsen, Bill,Beeley, Nigel,Sekiguchi, Yoshinori
-
p. 2565 - 2569
(2007/10/03)
-
- Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator
-
In this letter we report the synthesis and biochemical evaluation of selective, irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator (uPA). A diphenyl phosphonate group was introduced on the substratelike peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated. A guanylated benzyl group appeared the most promising side chain modification. A kapp value in the 103 M -1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.
- Joossens,Van Der Veken,Lambeir,Augustyns,Haemers
-
p. 2411 - 2413
(2007/10/03)
-
- NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME
-
The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.
- -
-
-
- Fused imidazopyridine derivatives as antihyperlipidemic agents
-
A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1and R2is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0is a bond or an optionally substituted bivalent hydrocarbon group; Z0is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3is hydrogen or an optionally substituted hydrocarbon group), or S(O)n(wherein n is to 0, 1 or 2); .........is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.
- -
-
-
- ANTITHROMBOTIC AGENTS
-
This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.
- -
-
-
- ANTITHROMBOTIC AGENTS
-
This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.
- -
-
-
- ANTITHROMBOTIC AGENTS
-
This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.
- -
-
-
- ANTITHROMBOTIC AGENTS
-
This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.
- -
-
-
- ANTITHROMBOTIC AGENTS
-
This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.
- -
-
-
- Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient
-
A thiazolidinone compound represented by general formula (I) or a pharmacoligically acceptable salt thereof, STR1 wherein W represents sulfur or oxygen and X represents --N(R1)--, or alternatively X represents sulfur or oxygen and W represents --N(R1)--, and R1 represents hydrogen, alkyl or substituted alkyl; R2 and R3 are the same or different from each other, and each represents hydrogen, alkyl, substituted alkyl, aryl, or 5- or 6-membered heteroaryl; R4 represents hydrogen, alkyl or substituted C1 -C4 alkyl; R5 represents substituted cycloalkyl which may contain nitrogen, provided the substituents include --B--ONO2 (wherein B represents a single bond or alkylene) as the indispensable member and alkyl groups as optional members; and A represents a single bond or alkylene, has an excellent anti-anginal effect and thus is useful as an angina pectoris remedy or preventive.
- -
-
-
- Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
-
The subject of the invention is the compounds of formula I STR1 in which Ar1 represents naphtyl, phenyl, quinolyl or isoquinolyl optionally substituted; Ar2 represents a phenyl or thienyl optionally substituted; R1, R
- -
-
-
- Use of src SH2 specific compounds to treat a bone resorption disease
-
Invented is a method of treating a bone resorption disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human src SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human lck SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such src SH2 domain.
- -
-
-
- Amine derivatives and process for producing the same
-
An amine derivative having a liquid crystal property over a wide temperature range and a process for production thereof are disclosed, the amine derivative being represented by formula (I) STR1 wherein A represents STR2 X1 and X2, which may be the same or different, each represents STR3 Y represents --O-- or STR4 R1 and R3, which may be the same or different, each represents a straight chain or branched chain alkyl group having 1 to 18 carbon atoms; R2 represents a hydrogen atom or a methyl group; m and n each represents 0 or 1; and p and q each represents 1 or 2, provided that p and q are 1 when n is 0, and p and q are not 2 at the same time when n is 1.
- -
-
-
- Anti-ulcer composition
-
An anti-peptic ulcer composition containing, as an active ingredient, a therapeutically effective amount of a compound having the formula (I): STR1 wherein A represents H2 NCH2 --, STR2 B represents STR3 D and E each independently re
- -
-
-